Aurinia Pharmaceuticals Inc. Non Peo Neo Avg Comp Actually Paid Amt
Aurinia Pharmaceuticals Inc. (AUPH) reported Non Peo Neo Avg Comp Actually Paid Amt of $5.14 million for the 12-month period ending 2025-12-31, per its DEF 14A filed 2026-04-21.
Financial Statements › Cash Flow › Other Cash Flow Items
ecd:NonPeoNeoAvgCompActuallyPaidAmt · last filed 2026-04-21
| Period end | Non Peo Neo Avg Comp Actually Paid Amt 12 month |
|---|---|
| 2025-12-31 | $5.14M DEF 14A · filed 2026-04-21 |
| 2024-12-31 | $2.43M DEF 14A · filed 2026-04-21 |
| 2023-12-31 | $5.27M DEF 14A · filed 2026-04-21 |
| 2022-12-31 | -$748.38K DEF 14A · filed 2026-04-21 |
| 2021-12-31 | $4.19M DEF 14A · filed 2026-04-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B |